Ask Warren

Samjin Pharmaceutical

005500 · KOSPI · ₩005500 · 삼진제약

₩19,250▼ ₩120 (0.62%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩80B₩68B₩81B₩83B₩75B₩71B₩84B₩81B
Cost of sales₩52B₩43B₩48B₩49B₩44B₩43B₩46B₩47B
Gross profit₩28B₩25B₩32B₩34B₩31B₩28B₩38B₩33B
Operating income₩7.2B₩3.6B₩4.2B₩9.8B₩8B₩4.8B₩9.2B₩9.2B
Net income₩4.7B₩1.4B₩8.9B₩6.8B₩4.7B₩3.7B₩6.9B₩4.5B
Net income to shareholders₩4.7B₩1.4B₩8.9B₩6.8B₩4.7B₩3.7B₩6.9B₩4.5B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩477B₩452B₩471B₩449B₩429B₩425B₩425B₩433B
Current assets₩193B₩183B₩192B₩189B₩166B₩164B₩159B₩151B
Cash and equivalents₩13B₩7.1B₩12B₩5.5B₩4.1B₩5.5B₩3.4B₩5.2B
Total liabilities₩178B₩175B₩180B₩185B₩171B₩173B₩164B₩150B
Current liabilities₩146B₩142B₩147B₩152B₩137B₩139B₩159B₩144B
Borrowings₩28B₩119B₩135B₩130B₩130B₩122B₩120B₩106B
Total equity₩299B₩278B₩290B₩265B₩258B₩252B₩262B₩283B
Shareholders' equity₩299B₩278B₩290B₩265B₩258B₩252B₩262B₩283B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩15B₩12B₩10B−₩1.4B₩11B₩4.9B−₩3.2B₩5.2B
Free cash flow₩15B₩12B₩10B−₩1.4B₩11B₩4.9B−₩3.2B₩5.2B
Dividends paid₩10B₩0₩0₩0——₩0₩0

Consolidated where available. Amounts in won.

Also known as: Samjin Pharmaceutical / 삼진제약 / 005500 / KRX:005500

Source: KRX statistical information